Ascendis Pharma A/S ADR (ASND)

Precedente Chiudi:

$135.98

Aprire:

$135

Volume 24 ore:

13,096

Capitalizzazione di mercato:

$7.70B

Reddito:

$288.35M

Utile/perdita netta:

$-521.73M

Rapporto P/E:

-12.03

EPS:

-11.3176

Flusso di cassa netto:

$-508.61M

1 W Prestazione:

-3.32%

1M Prestazione:

-8.49%

6M Prestazione:

+43.90%

1 anno Prestazione:

+43.17%

Intervallo 1D:

$134.95

$137.32

Portata 52W:

$83.75

$161.00

Ascendis Pharma A/S ADR Stock (ASND) Company Profile

Nome

Ascendis Pharma A/S ADR

Settore

Healthcare (1221)

Industria

Biotechnology (698)

Telefono

45 70 22 22 44

Indirizzo

Tuborg Boulevard 5, Hellerup

Dipendente

137

Cinguettio

Prossima data di guadagno

2024-05-30

Ultimi documenti SEC

ASND's Discussions on Twitter

Ascendis Pharma A/S ADR Stock (ASND) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-12-20	Iniziato	Jefferies	Buy
2023-06-14	Ripresa	Credit Suisse	Neutral
2023-04-05	Downgrade	Oppenheimer	Outperform → Perform
2023-04-04	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2023-04-03	Downgrade	Credit Suisse	Outperform → Neutral
2022-10-20	Iniziato	Goldman	Buy
2022-08-30	Ripresa	Berenberg	Buy
2022-03-28	Ripresa	Wedbush	Outperform
2022-03-15	Aggiornamento	BofA Securities	Neutral → Buy
2022-03-01	Iniziato	Citigroup	Buy
2022-02-14	Aggiornamento	Oppenheimer	Perform → Outperform
2022-01-06	Iniziato	Cowen	Market Perform
2021-12-08	Iniziato	Wells Fargo	Overweight
2021-10-20	Downgrade	BofA Securities	Buy → Neutral
2021-03-30	Downgrade	Oppenheimer	Outperform → Perform
2021-03-11	Ripresa	Stifel	Buy
2020-12-17	Iniziato	Berenberg	Buy
2020-09-14	Ripresa	JP Morgan	Overweight
2020-03-20	Iniziato	Oppenheimer	Outperform
2019-10-11	Iniziato	Morgan Stanley	Overweight
2019-03-25	Iniziato	Evercore ISI	Outperform
2019-01-24	Iniziato	Cantor Fitzgerald	Overweight
2019-01-24	Aggiornamento	Leerink Partners	Mkt Perform → Outperform
2018-06-26	Iniziato	Stifel	Buy
2018-04-02	Reiterato	Leerink Partners	Mkt Perform
2017-05-11	Iniziato	JP Morgan	Overweight
2017-03-09	Downgrade	Leerink Partners	Outperform → Mkt Perform
2017-02-09	Iniziato	Credit Suisse	Outperform
2016-09-26	Iniziato	Wedbush	Outperform

Mostra tutto

Ascendis Pharma A/S ADR Borsa (ASND) Ultime notizie

Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024

GlobeNewswire Inc.

Why Earnings Season Could Be Great for Ascendis Pharma (ASND)

Zacks Investment Research

United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

GlobeNewswire Inc.

Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?

Zacks Investment Research

Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?

Zacks Investment Research

The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys

Zacks Investment Research

Ascendis Pharma A/S ADR Azioni (ASND) Dati Finanziari

Ascendis Pharma A/S ADR (ASND) Reddito 2024

Ascendis Pharma A/S ADR (ASND) Reddito netto 2024

Ascendis Pharma A/S ADR (ASND) Flusso di cassa 2024

Ascendis Pharma A/S ADR (ASND) Utile per azione 2024